Unusual 11 Midday Movers 02/01: (KTCC) (MGAM) (COCO) (SGMO) Higher; (HVB) (JDAS) (IXYS) Lower
Tweet
Share
E-mail
Get Alerts KTCC Hot Sheet
Join SI Premium – FREE
Key Tronic Corp (NASDAQ: KTCC) 35% HIGHER; reported Q2 EPS of $0.30, versus $0.17 reported last year. Revenue for the quarter came in at $84.5 million, versus $61 million reported last year. For the third quarter of fiscal 2012, the Company expects to report revenue in the range of $92 million to $97 million, and earnings in the range of $0.30 to $0.35 per diluted share. The expected earnings range assumes an effective tax rate of 30%.
Multimedia Games Holding Company, Inc. (NASDAQ: MGAM) 32.3% HIGHER; reported Q1 EPS of $0.21, $0.17 better than the analyst estimate of $0.04. Revenue for the quarter came in at $34.8 million versus the consensus estimate of $30.96 million. Sees FY2012 EPS of $0.42-$0.45, versus prior guidance of $0.23-$0.26 and the consensus of $0.32.
Corinthian Colleges, Inc. (NASDAQ: COCO) 31.7% HIGHER; reported Q2 EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $415.5 million versus the consensus estimate of $415.28 million. Sees Q3 adj-EPS 15-17 cents, which compares to the Street estimate of 13 cents. Sees FY12 adj-EPS of 30-33 cents, which compares to the Street estimate of 24 cents.
Medivation, Inc. (NASDAQ: MDVN) 26.2% HIGHER; Medivation and Astellas Pharma Inc. announced positive results on all efficacy endpoints from the Phase 3 AFFIRM trial of the investigational drug MDV3100 in men with prostate cancer previously treated with chemotherapy. Data will be highlighted in a late-breaking oral presentation at the upcoming 2012 Genitourinary Cancers Symposium in San Francisco, CA on Thursday, February 2.
Sangamo BioSciences, Inc. (NASDAQ: SGMO) 26.1% HIGHER; Shire plc (NASDAQ: SHPGY) and Sangamo have entered into a collaboration and license agreement to develop therapeutics for hemophilia and other monogenic diseases based on Sangamo's zinc finger DNA-binding protein technology.
Radisys Corp (NASDAQ: RSYS) 22.6% HIGHER; reported Q4 EPS of $0.05, $0.05 better than the analyst estimate of $0.00. Revenue for the quarter came in at $79.5 million versus the consensus estimate of $78.3 million. Sees Q1 EPS between $0.00 to $0.06, versus consensus of $0.04. Sees Q1 sales of $75-$81 million, versus the consensus of $75.8 million.
Hudson Valley Holding Corp. (NYSE: HVB) 20.3% LOWER; reported Q4 adjusted EPS of $0.27, versus $0.36 reported last year. The company also was downgraded by Stifel Nicolaus today to a Hold rating.
Jda Software Group, Inc. (NASDAQ: JDAS) 16.7% LOWER; reported Q4 EPS of $0.65, $0.02 better than the analyst estimate of $0.63. Revenue for the quarter came in at $174.2 million versus the consensus estimate of $172.8 million.
IXYS Corp (NASDAQ: IXYS) 15.8 LOWER; reported Q3 EPS of $0.18, $0.07 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $80 million versus the consensus estimate of $94 million.
Unisys Corp. (NYSE: UIS) 12.6% LOWER; reported Q4 EPS of $2.08, $0.58 better than the analyst estimate of $1.50. Revenue for the quarter came in at $985.3 million versus the consensus estimate of $1.02 billion.
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) 11.1% LOWER; today announced that the Company's Board of Directors has appointed David Y. Norton, a member of the Savient Board and former Company Group Chairman, Global Pharmaceuticals for Johnson & Johnson, to the role of Interim Chief Executive Officer, effective immediately. Mr. Norton succeeds John H. Johnson who has resigned as Chief Executive Officer, President and a director of Savient to become President, Chief Executive Officer and Chairman-Elect of Dendreon Corporation (Nasdaq: DNDN). The Board will conduct a search process for a permanent Chief Executive Officer. The stock was also downgraded at Cowen.
Multimedia Games Holding Company, Inc. (NASDAQ: MGAM) 32.3% HIGHER; reported Q1 EPS of $0.21, $0.17 better than the analyst estimate of $0.04. Revenue for the quarter came in at $34.8 million versus the consensus estimate of $30.96 million. Sees FY2012 EPS of $0.42-$0.45, versus prior guidance of $0.23-$0.26 and the consensus of $0.32.
Corinthian Colleges, Inc. (NASDAQ: COCO) 31.7% HIGHER; reported Q2 EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $415.5 million versus the consensus estimate of $415.28 million. Sees Q3 adj-EPS 15-17 cents, which compares to the Street estimate of 13 cents. Sees FY12 adj-EPS of 30-33 cents, which compares to the Street estimate of 24 cents.
Medivation, Inc. (NASDAQ: MDVN) 26.2% HIGHER; Medivation and Astellas Pharma Inc. announced positive results on all efficacy endpoints from the Phase 3 AFFIRM trial of the investigational drug MDV3100 in men with prostate cancer previously treated with chemotherapy. Data will be highlighted in a late-breaking oral presentation at the upcoming 2012 Genitourinary Cancers Symposium in San Francisco, CA on Thursday, February 2.
Sangamo BioSciences, Inc. (NASDAQ: SGMO) 26.1% HIGHER; Shire plc (NASDAQ: SHPGY) and Sangamo have entered into a collaboration and license agreement to develop therapeutics for hemophilia and other monogenic diseases based on Sangamo's zinc finger DNA-binding protein technology.
Radisys Corp (NASDAQ: RSYS) 22.6% HIGHER; reported Q4 EPS of $0.05, $0.05 better than the analyst estimate of $0.00. Revenue for the quarter came in at $79.5 million versus the consensus estimate of $78.3 million. Sees Q1 EPS between $0.00 to $0.06, versus consensus of $0.04. Sees Q1 sales of $75-$81 million, versus the consensus of $75.8 million.
Hudson Valley Holding Corp. (NYSE: HVB) 20.3% LOWER; reported Q4 adjusted EPS of $0.27, versus $0.36 reported last year. The company also was downgraded by Stifel Nicolaus today to a Hold rating.
Jda Software Group, Inc. (NASDAQ: JDAS) 16.7% LOWER; reported Q4 EPS of $0.65, $0.02 better than the analyst estimate of $0.63. Revenue for the quarter came in at $174.2 million versus the consensus estimate of $172.8 million.
IXYS Corp (NASDAQ: IXYS) 15.8 LOWER; reported Q3 EPS of $0.18, $0.07 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $80 million versus the consensus estimate of $94 million.
Unisys Corp. (NYSE: UIS) 12.6% LOWER; reported Q4 EPS of $2.08, $0.58 better than the analyst estimate of $1.50. Revenue for the quarter came in at $985.3 million versus the consensus estimate of $1.02 billion.
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) 11.1% LOWER; today announced that the Company's Board of Directors has appointed David Y. Norton, a member of the Savient Board and former Company Group Chairman, Global Pharmaceuticals for Johnson & Johnson, to the role of Interim Chief Executive Officer, effective immediately. Mr. Norton succeeds John H. Johnson who has resigned as Chief Executive Officer, President and a director of Savient to become President, Chief Executive Officer and Chairman-Elect of Dendreon Corporation (Nasdaq: DNDN). The Board will conduct a search process for a permanent Chief Executive Officer. The stock was also downgraded at Cowen.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Etsy upgraded to buy at BofA on durable growth, buyback potential
- 'We expect salesforce.com (CRM) to capture a meaningful share of next-gen agentic workflows': Cantor
- Rubrik Inc (RBRK) PT Raised to $120 at Cantor Fitzgerald Into Q2 Earnings
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Stifel, Cowen & Co, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
